Squarepoint Ops LLC Sells 107,750 Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)

Squarepoint Ops LLC trimmed its holdings in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 55.6% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 86,044 shares of the biotechnology company's stock after selling 107,750 shares during the period. Squarepoint Ops LLC owned 0.07% of Arrowhead Pharmaceuticals worth $1,618,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. R Squared Ltd acquired a new stake in shares of Arrowhead Pharmaceuticals in the fourth quarter worth $38,000. Van ECK Associates Corp lifted its stake in shares of Arrowhead Pharmaceuticals by 72.3% in the fourth quarter. Van ECK Associates Corp now owns 2,978 shares of the biotechnology company's stock worth $56,000 after buying an additional 1,250 shares during the last quarter. KBC Group NV lifted its stake in shares of Arrowhead Pharmaceuticals by 45.9% in the fourth quarter. KBC Group NV now owns 5,224 shares of the biotechnology company's stock worth $98,000 after buying an additional 1,644 shares during the last quarter. Envestnet Portfolio Solutions Inc. acquired a new stake in shares of Arrowhead Pharmaceuticals in the fourth quarter worth $190,000. Finally, Cibc World Markets Corp acquired a new stake in shares of Arrowhead Pharmaceuticals in the fourth quarter worth $210,000. 62.61% of the stock is currently owned by institutional investors and hedge funds.

Arrowhead Pharmaceuticals Price Performance

Shares of ARWR stock traded up $0.21 during mid-day trading on Tuesday, reaching $16.61. The company's stock had a trading volume of 1,937,025 shares, compared to its average volume of 1,522,001. The firm's 50-day moving average is $13.49 and its two-hundred day moving average is $17.38. The company has a market cap of $2.29 billion, a P/E ratio of -3.21 and a beta of 0.89. Arrowhead Pharmaceuticals, Inc. has a 1-year low of $9.57 and a 1-year high of $30.41. The company has a debt-to-equity ratio of 7.27, a quick ratio of 6.09 and a current ratio of 6.09.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last released its quarterly earnings data on Monday, May 12th. The biotechnology company reported $2.75 EPS for the quarter, topping analysts' consensus estimates of ($0.06) by $2.81. The business had revenue of $542.71 million for the quarter, compared to the consensus estimate of $116.27 million. During the same period in the previous year, the business posted ($1.02) earnings per share. On average, research analysts predict that Arrowhead Pharmaceuticals, Inc. will post -2.42 earnings per share for the current year.

Insider Activity

In other news, CEO Christopher Richard Anzalone sold 51,425 shares of the company's stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $15.07, for a total value of $774,974.75. Following the sale, the chief executive officer now owns 4,062,377 shares of the company's stock, valued at approximately $61,220,021.39. This represents a 1.25% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In the last ninety days, insiders have sold 142,547 shares of company stock worth $1,764,709. Company insiders own 4.30% of the company's stock.

Wall Street Analysts Forecast Growth

ARWR has been the subject of a number of analyst reports. HC Wainwright restated a "buy" rating and issued a $80.00 price objective on shares of Arrowhead Pharmaceuticals in a research note on Tuesday, May 20th. Wall Street Zen upgraded shares of Arrowhead Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Thursday, May 22nd. Chardan Capital restated a "buy" rating and issued a $60.00 price objective on shares of Arrowhead Pharmaceuticals in a research note on Tuesday, May 13th. B. Riley reiterated a "buy" rating and set a $38.00 target price (down from $51.00) on shares of Arrowhead Pharmaceuticals in a research note on Friday, February 14th. Finally, Royal Bank of Canada reiterated an "outperform" rating and set a $42.00 target price on shares of Arrowhead Pharmaceuticals in a research note on Tuesday, February 11th. Four investment analysts have rated the stock with a hold rating and six have given a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $42.13.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.